In line with these observations, we also noted marked differences in the pharmacokinetic profiles, and especially in the tumor vs. pancreas uptake, across a series of [99mTc]Tc-based GRPR radioantagonists, [99mTc]Tc-DB1 mimics [23]. Here, VEZF1 is linked to neoplasm.